SCHEDULE: Vanguard Group Amends Dyne Therapeutics Stake to Zero

The Vanguard Group has amended its Schedule 13G filing for Dyne Therapeutics Inc., reporting zero beneficial ownership following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 2 to its Schedule 13G for Dyne Therapeutics Inc. Common Stock.
• The filing reports 0 shares beneficially owned by The Vanguard Group, representing 0% of the class of Common Stock.
• This change is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of Vanguard will now report beneficial ownership separately (on a disaggregated basis) in reliance on SEC Release No. 34-39538.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing. It reflects an internal organizational change at The Vanguard Group and does not provide any new information regarding Dyne Therapeutics Inc.'s operational or financial performance.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that Schedule 13G filings primarily reflect passive investment positions and changes in reporting structure, rather than active investment decisions or strategic shifts related to the issuer's industry. This particular filing highlights an internal operational adjustment by a major asset manager, The Vanguard Group, which is a common occurrence in large, complex financial institutions.

Stakeholder Impact

• This filing primarily impacts The Vanguard Group's internal reporting structure and does not directly affect Dyne Therapeutics Inc.'s shareholders, employees, customers, suppliers, or creditors.
• It clarifies that Vanguard, as a single entity, no longer holds a reportable stake, but its underlying funds/subsidiaries may still hold shares and report them separately.

Key Dates

Keywords

Dyne Therapeutics, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Management, Institutional Investor